{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:47:50Z","timestamp":1761986870460,"version":"build-2065373602"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12325-025-03370-w","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T07:22:37Z","timestamp":1758612157000},"page":"5727-5741","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Strategic Roadmap to Support Communication on and Acceptance of Surrogate Endpoints: The REnal Surrogacy accEpTance in Chronic Kidney Disease (RESET CKD) Collaboration"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6546-7769","authenticated-orcid":false,"given":"Juan Jos\u00e9","family":"Garcia Sanchez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Trapero-Bertran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3607-0508","authenticated-orcid":false,"given":"Oriana","family":"Ciani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7843-4608","authenticated-orcid":false,"given":"Bruno","family":"Detournay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loreto","family":"Gesualdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiddo J. L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley A.","family":"Inker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smeeta","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dustin J.","family":"Little","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvin","family":"Sinsakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0817-0704","authenticated-orcid":false,"given":"You-Seon","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3043-6011","authenticated-orcid":false,"given":"Rod S.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"issue":"1","key":"3370_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104251","volume":"30","author":"LT Bloem","year":"2025","unstructured":"Bloem LT, Leufkens HGM, Berends SE, et al. Stimulating development of innovative medicines in the European Union: does a new definition for unmet medical need add value? Drug Discov Today. 2025;30(1):104251.","journal-title":"Drug Discov Today"},{"key":"3370_CR2","unstructured":"Advanced Research Projects Agency for Health. About us. https:\/\/arpa-h.gov\/about. Accessed May\u00a013, 2025."},{"key":"3370_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102614","volume":"72","author":"GM Chertow","year":"2024","unstructured":"Chertow GM, Correa-Rotter R, Eckardt K-U, et al. Projecting the clinical burden of chronic kidney disease at the patient level (Inside CKD): a microsimulation modelling study. eClinicalMedicine. 2024;72:102614.","journal-title":"eClinicalMedicine"},{"issue":"3","key":"3370_CR4","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1093\/ndt\/gfac140","volume":"38","author":"L Fried","year":"2023","unstructured":"Fried L, Schmedt N, Folkerts K, et al. High unmet treatment needs in patients with chronic kidney disease and type\u00a02 diabetes: real-world evidence from a US claims database. Nephrol Dial Transplant. 2023;38(3):630\u201343.","journal-title":"Nephrol Dial Transplant"},{"issue":"17","key":"3370_CR5","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272\u201387.","journal-title":"Cardiovasc Res"},{"issue":"10356","key":"3370_CR6","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/S0140-6736(22)01273-9","volume":"400","author":"D Stolz","year":"2022","unstructured":"Stolz D, Mkorombindo T, Schumann DM, et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet. 2022;400(10356):921\u201372.","journal-title":"Lancet"},{"issue":"3","key":"3370_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00467-015-3104-8","volume":"31","author":"EA Hartung","year":"2016","unstructured":"Hartung EA. Biomarkers and surrogate endpoints in kidney disease. Pediatr Nephrol. 2016;31(3):381\u201391.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"3370_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12325-021-02006-z","volume":"39","author":"JJ Garcia Sanchez","year":"2022","unstructured":"Garcia Sanchez JJ, Thompson J, Scott DA, et al. Treatments for chronic kidney disease: a systematic literature review of randomized controlled trials. Adv Ther. 2022;39(1):193\u2013220.","journal-title":"Adv Ther"},{"issue":"6","key":"3370_CR9","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/COH.0b013e32833ed177","volume":"5","author":"K Strimbu","year":"2010","unstructured":"Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010;5(6):463\u20136.","journal-title":"Curr Opin HIV AIDS"},{"key":"3370_CR10","volume":"65","author":"O Ciani","year":"2023","unstructured":"Ciani O, Manyara AM, Davies P, et al. A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials. EClinMed. 2023;65:102283.","journal-title":"EClinMed"},{"key":"3370_CR11","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Response biomarker. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK402286\/. Accessed May\u00a013, 2025."},{"issue":"1","key":"3370_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/01.qai.0000247227.22504.ce","volume":"44","author":"D Follmann","year":"2007","unstructured":"Follmann D, Duerr A, Tabet S, et al. Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop. J Acquir Immune Defic Syndr. 2007;44(1):49\u201360.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3370_CR13","unstructured":"US Food and Drug Administration. Table of surrogate endpoints that were the basis of drug approval or licensure. https:\/\/www.fda.gov\/drugs\/development-resources\/table-surrogate-endpoints-were-basis-drug-approval-or-licensure. Accessed May\u00a013, 2025."},{"key":"3370_CR14","unstructured":"European Medicines Agency. Qualification opinion for GFR slope as a validated surrogate endpoint for RCT in CKD (EMA\/SA\/00000104642). 2023."},{"issue":"10","key":"3370_CR15","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s40273-020-00935-1","volume":"38","author":"B Grigore","year":"2020","unstructured":"Grigore B, Ciani O, Dams F, et al. Surrogate endpoints in health technology assessment: an international review of methodological guidelines. Pharmacoeconomics. 2020;38(10):1055\u201370.","journal-title":"Pharmacoeconomics"},{"key":"3370_CR16","unstructured":"National Institute for Health and Care Excellence (England), Canada\u2019s Drug Agency (CDA-AMC), Institute for Clinical and Economic Review (ICER) (US), et al. Surrogate endpoints in cost-effectiveness analysis for use in health technology assessment. https:\/\/www.nice.org.uk\/about\/what-we-do\/our-research-work\/our-projects-and-partners#surrogate-endpoints-in-cost-effectiveness-analysis-for-use-in-health-technology-assessment. Accessed May\u00a02025."},{"key":"3370_CR17","unstructured":"European Medicines Agency. Guideline on the clinical investigation of medicinal products to prevent development\/slow progression of chronic renal insufficiency. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-prevent-developmentslow-progression-chronic-renal-insufficiency_en.pdf. Accessed May\u00a07, 2024."},{"key":"3370_CR18","unstructured":"European Medicines Agency. Committee for medicinal products for human use. Guideline on Clinical Trials in Small Populations (CHMP\/EWP\/83561\/2005). 2006."},{"key":"3370_CR19","unstructured":"Japan Ministry of Health, Labour and Welfare. Release of clinical trial guidance to facilitate the speedy and accurate approval and development of medical devices (provisional translation). https:\/\/www.pmda.go.jp\/files\/000237132.pdf. Accessed 21 Aug 2024."},{"key":"3370_CR20","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. https:\/\/www.nice.org.uk\/process\/pmg36\/resources\/nice-health-technology-evaluations-the-manual-pdf-72286779244741. Accessed May\u00a013, 2025."},{"key":"3370_CR21","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen [Institute for Quality and Efficiency in Health Care]. Allgemeine methoden [General methods]. https:\/\/www.iqwig.de\/methoden\/allgemeine-methoden_entwurf-fuer-version-7.pdf. Accessed May\u00a013, 2025."},{"key":"3370_CR22","unstructured":"European Network for Health Technology Assessment. Endpoints used in relative effectiveness assessment: Surrogate endpoints. https:\/\/www.eunethta.eu\/wp-content\/uploads\/2018\/01\/Endpoints-used-in-Relative-Effectiveness-Assessment-Surrogate-Endpoints_Amended-JA1-Guideline_Final-Nov-2015.pdf. Accessed 21 Aug 2024."},{"key":"3370_CR23","unstructured":"European Network for Health Technology Assessment. EUnetHTA 21 \u2013 Individual Practical Guideline Document: D4.4 \u2013 Outcomes (Endpoints). https:\/\/www.eunethta.eu\/wp-content\/uploads\/2023\/01\/EUnetHTA-21-D4.4-practical-guideline-on-Endpoints-v1.0.pdf. Accessed 21 Aug 2024."},{"key":"3370_CR24","unstructured":"France Haute Autorit\u00e9 de Sant\u00e9. Methodological guidance: Choices in methods for economic evaluation. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2020-11\/methodological_guidance_2020_-choices_in_methods_for_economic_evaluation.pdf. Accessed 21 Aug 2024."},{"key":"3370_CR25","unstructured":"France Haute Autorit\u00e9 de Sant\u00e9. Doctrine de la commission de la transparence (CT): Principes d\u2019\u00e9valuation de la CT relatifs aux m\u00e9dicaments en vue de leur acc\u00e8s au remboursement. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2021-03\/doctrine_ct.pdf. Accessed 21 Aug 2024."},{"key":"3370_CR26","unstructured":"US Institute for Clinical and Economic Review. Strengthening the accelerated approval pathway: An analysis of potential policy reforms and their impact on uncertainty, access, innovation, and costs. https:\/\/icer.org\/wp-content\/uploads\/2021\/04\/Strengthening-the-Accelerated-Approval-Pathway-_-ICER-White-Paper-_-April-2021.pdf. Accessed 21 Aug 2024."},{"key":"3370_CR27","unstructured":"Grupo de Evaluaci\u00f3n de Novedades Estandarizaci\u00f3n e Investigaci\u00f3n en Selecci\u00f3n de Medicaments de la Sociedad Espa\u00f1ola de Farmacia Hospitalaria. Gu\u00eda de evaluaci\u00f3n econ\u00f3mica e impacto presupuestario en los informes de evaluaci\u00f3n de medicamentos: Gu\u00eda Pr\u00e1ctica. https:\/\/gruposdetrabajo.sefh.es\/genesis\/genesis\/Documents\/GUIA_EE_IP_GENESIS-SEFH_19_01_2017.pdf. Accessed 20 Aug 2024."},{"issue":"9","key":"3370_CR28","doi-asserted-by":"publisher","first-page":"e1002873","DOI":"10.1371\/journal.pmed.1002873","volume":"16","author":"BC Schuster","year":"2019","unstructured":"Schuster BC, Brhlikova P, Heath J, McGettigan P. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: a cross-sectional study of products authorised 2011\u20132018. PLoS Med. 2019;16(9):e1002873.","journal-title":"PLoS Med"},{"key":"3370_CR29","doi-asserted-by":"crossref","unstructured":"Canadian Agency for Drugs and Technologies in Health. Real-world evidence steering Committee [archived]. https:\/\/www.cda-amc.ca\/real-world-evidence-steering-committee. Accessed 12 Dec 2024.","DOI":"10.1109\/DS-RT62209.2024.00008"},{"key":"3370_CR30","unstructured":"National Institute for Health and Care Excellence. Our committees. https:\/\/test.nice.org.uk\/Get-Involved\/our-committees. Accessed 13 May\u00a02025."},{"issue":"7","key":"3370_CR31","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/nrd.2016.81","volume":"15","author":"O Ciani","year":"2016","unstructured":"Ciani O, Buyse M, Drummond M, Rasi G, Saad ED, Taylor RS. Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework. Nat Rev Drug Discov. 2016;15(7):516.","journal-title":"Nat Rev Drug Discov"},{"key":"3370_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078525","volume":"386","author":"AM Manyara","year":"2024","unstructured":"Manyara AM, Davies P, Stewart D, et al. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525.","journal-title":"BMJ"},{"key":"3370_CR33","unstructured":"International Society for Pharmacoeconomics and Outcomes Research. Surrogate Endpoint Statistical Evaluation for HTA Decision Making: Task Force. https:\/\/www.ispor.org\/member-groups\/task-forces\/surrogate-endpoint-statistical-assessment-for-hta-decision-making. Accessed 13 May\u00a02025."},{"issue":"9","key":"3370_CR34","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1681\/ASN.2019010008","volume":"30","author":"ME Grams","year":"2019","unstructured":"Grams ME, Sang Y, Ballew SH, et al. Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data. J Am Soc Nephrol. 2019;30(9):1746\u201355.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"3370_CR35","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","volume":"29","author":"LA Inker","year":"2023","unstructured":"Inker LA, Collier W, Greene T, et al. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat Med. 2023;29(7):1867\u201376.","journal-title":"Nat Med"},{"issue":"9","key":"3370_CR36","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1681\/ASN.2019010007","volume":"30","author":"LA Inker","year":"2019","unstructured":"Inker LA, Heerspink HJL, Tighiouart H, et al. GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials. J Am Soc Nephrol. 2019;30(9):1735\u201345.","journal-title":"J Am Soc Nephrol"},{"key":"3370_CR37","doi-asserted-by":"publisher","unstructured":"Taylor RS, Heerspink HJL, Buyse M, et al. Use of surrogate endpoints in health technology assessment and reimbursement of treatments for the management of chronic kidney disease. eClinicalMedicine. 2025; 88:103465. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103465.","DOI":"10.1016\/j.eclinm.2025.103465"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03370-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03370-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03370-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:45:35Z","timestamp":1761986735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03370-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3370"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03370-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Christoph Wanner has received honoraria for steering committee membership, advisory board participation, and lecturing from Alexion, Amgen, Amicus, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Vifor, Eli Lilly, GSK, Idorsia, Novartis, Novo Nordisk, and Sanofi. Oriana Ciani has received honoraria for advisory board participation and consultancy from AstraZeneca, MSD, Lumanity, and Cencora. Bruno Detournay has received personal compensation for advisory board participation and speaker fees from Abbott, AstraZeneca, CEMKA, Cerba, Novo Nordisk, Sanofi Winthrop Industrie, Eli Lilly, Lumanity, Janssen, MSD, Continuum+, and Pfizer. Marta Trapero-Bertran has received honoraria for advisory board participation from AstraZeneca and Boehringer Ingelheim, and from Novartis for in-company teaching on economic evaluation methods. Smeeta Sinha has received honoraria from AstraZeneca, Boehringer Ingelheim, CSL Vifor, Novartis, GSK, Sanofi-Genzyme, Inozyme Pharma, Menarini, Amicus, Stada, Chiesi, Bayer, and Santhera; and grant funding from AstraZeneca, Novartis, CSL Vifor, Johnson & Johnson, and Sanofi-Genzyme. Loreto Gesualdo has received research grants from Abionix, Sanofi and Astrazeneca payed to his institution; He has received speaker honoraria from Bayer and Werfen; served as consultant for Baxter, Tavere, Astrazeneca, GSK, Novartis, Chinook, Roche, Reate, Nestle, Otsuka, Gilead Science, Bayer, and Vifor Fresenius. Hiddo J. L. Heerspink reports funding to conduct clinical trials from AstraZeneca, Bayer, Boehringer Ingelheim, Janssen and Novo Nordisk (payments to his institution, the University of Groningen); consulting fees from AstraZeneca, Alexion, Alnylam, Bayer, Boehringer Ingelheim, BioCity Biopharma, Dimerix, Eli Lilly, Gilead, Idorsia, Janssen, Novartis, Novo Nordisk, Roche and Travere Therapeutics (payments to his institution, the University of Groningen); honoraria for lectures from AstraZeneca, Bayer and Novo Nordisk; and support for traveling to and attending the American Diabetes Association meeting and the American Society of Nephrology meeting from AstraZeneca and Eli Lilly (payment to his institution, the University of Groningen). Lesley A. Inker reports funding to Tufts Medical Center from National Institutes of Health (NIH), National Kidney Foundation (NKF), Chinook, R3R, Otsuka Pharmaceutical, Alexion Pharmaceuticals, and Novartis; consulting agreements to Tufts Medical Center from Alexion Pharmaceuticals and AstraZeneca; and consulting agreements from Diamerix. Juan Jose Garcia Sanchez, Dustin J. Little, Marvin Sinsakul, and You-Seon Nam are employees of AstraZeneca. Rod S. Taylor reports research grant from UK Medical Research Council (MRC) funding for the SPIRIT\/CONSORT-Surrogate extension development (grant reference MR\/V038400\/1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}